u/milan_mensah

the memo field matters on the chains that use one

the same token exists on several chains and they are not interchangeable

Lyophilisation removes the water that drives most degradation pathways. That is why the dry cake is comparatively robust and the reconstituted solution is not.

Are you reading the publication or a summary?

I would not treat one pharmacy’s quote as a national price.

This is the split the whole board depends on. Authorisation is European; payment is national.

Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for.

How many separate lots has anyone here tested?

Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Not convinced.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Regional stock changes the question rather than answering it: shorter lanes mean less exposure and fewer variables, which is why the warehouse question is worth asking before ordering in summer.

Agreed that quote expiry is ordinary. Rates move and a time-limited quote is not a pressure tactic on its own.

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

Is this a line they hold in regional stock or is it shipping from origin?

This is the distinction that resolves most threads here — powder and solution are different problems.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

Put a logger in three consecutive orders. Two never went above the range at all and the third spent four hours warm on a Friday. Cost me almost nothing to stop wondering.

ask what storage condition the stability statement was written against

Small fix — refrigerated, not frozen, once it is in solution.

Nothing here is medical or legal advice, and eligibility questions have national answers that a pharmacist where you live can give you in minutes.

This is the split the whole board depends on. Authorisation is European; payment is national.

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.

a press release is not a publication

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

Does the effect persist with continued dosing or does tolerance develop?

Push back: an unconfirmed transaction is not a missing payment. Wait for confirmations before escalating.

the hepatic data is what makes this compound different from the others

the door shelf is the worst place in the fridge

Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.

Read a press release and the publication three months apart.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

That figure is from the obesity programme, and this thread is about the hepatic one.

Which networks did they list as accepted?

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

Disagree — a quote expiry is normal when a rate is being held. Pressure to decide immediately is a different thing.

Asked SSA which lines they hold regionally and got a straight list back. That answered my summer ordering question completely.

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.